The “Aging Males’ Symptoms” Scale (AMS): predictive value for lowered circulating androgens

Figures & data

Table I.  Severity of climacteric symptoms according to the AMS Questionnaire in the studied population (n = 146).

	No. of patients	%
No symptoms (17–26 points)	37	25.3
Mild symptoms (27–36 points)	43	29.5
Moderate symptoms (37–49 points)	43	29.5
Severe symptoms (>50 points)	23	15.8
Total	146	100.0

Table II.  Prevalence of pathological AMS (≥37) and changes in mean serum levels of total testosterone (tT), SHBG and calculated free testosterone (fT) in relation to age.

Age (years)	AMS score ≥37 n/N (%)	Mean tT nmol/l	Mean SHBG nmol/l	Mean fT pmol/l
<40	6/14 (42.8)	14.8 ± 6.3	30.4 ± 12.1	335.4 ± 141.3
40–49	14/30 (46.7)	13.1 ± 5.6	33.2 ± 18.2	258.2 ± 92.8
50–59	19/37 (51.4)	12.8 ± 5.1	36.9 ± 19.3	253.6 ± 86.7
60–69	17/40 (42.5)	11.8 ± 6.2	42.3 ± 18.3	215.0 ± 111.0
≥70	10/25 (40.0)	13.6 ± 5.9	56.8 ± 23.8	209.6 ± 82.2
Total	66/146 (45.2)	12.9 ± 5.7	38.9 ± 18.7	245.6 ± 105.7

fT, free testosterone, SHBG, sexual hormone binding globulin; tT, total testosterone.

Figure 1.  Changes in mean serum levels of total testosterone (tT), SHBG and calculated free testosterone (fT) in relation to age.

Figure 2.  Correlation of total testosterone (tT), SHBG and calculated free testosterone (fT) with age.